NIH begins ZMapp trial; Sanofi nears EU nod with new insulin;

@FierceBiotech: From @FiercePharmAsia, Novartis' Japan unit hit with a 15-day sales ban. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vitae slammed as another BACE inhibitor trips and Boehringer halts Alzheimer's study. Report | Follow @JohnCFierce

@DamianFierce: While $MRK and $ACT embrace antibiotics, $AZN is tiptoeing out. Report | Follow @DamianFierce

> The National Institutes of Health has kicked off its clinical trial of Mapp Biopharmaceutical's ZMapp, a promising treatment for Ebola. More

> Sanofi's ($SNY) Toujeo, a long-acting insulin, secured an EU recommendation just days after picking up FDA approval, stoking the companies hopes of usurping the soon-to-come-off-patent Lantus. Story

> In a late-stage trial, the combination of Bristol-Myers Squibb's ($BMY) daclatasvir and Gilead Sciences' ($GILD) Sovaldi charted a 97% cure rate for hepatitis C patients who also have HIV. News

Medical Device News

@FierceMedDev: Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Scientific launches upgraded endoscope, says it will reduce repeat procedures. Article | Follow @VarunSaxena2

@EmilyWFierce: Vigilant Biosciences reels in $5.5M for oral cancer test. More from FierceDiagnostics | Follow @EmilyWFierce

> Nikon to buy optical imaging player Optos for $400M in med tech expansion bid. Story

> UnitedHealth to require prior authorization for gynecological procedures amid morcellator pushback. More

> Device for remote and autonomous management of Parkinson's being tested in Europe. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaManufacturing: Impax reports significant jump in revenues as it gets plant problems behind it. Article | Follow @FiercePharma

@EricPFierce: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Pfizer, Novartis get MenB ACIP nod--but not the one they're really after. More from FierceVaccines | Follow @CarlyHFierce

> Pfizer, Novartis: CDC's MenB nod is too narrow. Item

> Sanofi's Toujeo gets the love from EU regulators that FDA withheld. Story

> Gilead looks overseas to guard profits for hep C blockbuster Sovaldi. Article

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.